4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report sent to investors on Saturday morning,Weiss Ratings reports.

FDMT has been the topic of several other research reports. BMO Capital Markets downgraded 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Chardan Capital reduced their price objective on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Bank of America lowered their target price on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Morgan Stanley dropped their target price on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a report on Monday, January 13th. Finally, Leerink Partners lowered their price target on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $30.63.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ FDMT opened at $3.93 on Friday. The firm has a market cap of $181.97 million, a PE ratio of -1.38 and a beta of 2.83. 4D Molecular Therapeutics has a one year low of $3.58 and a one year high of $36.25. The firm has a fifty day moving average of $4.68 and a 200 day moving average of $7.30.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). On average, equities analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in 4D Molecular Therapeutics during the fourth quarter worth about $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at approximately $50,000. PNC Financial Services Group Inc. raised its position in shares of 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after buying an additional 3,630 shares during the period. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after acquiring an additional 9,737 shares during the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in 4D Molecular Therapeutics in the fourth quarter worth approximately $56,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.